Pathological complete response with Pembrolizumab in combination with chemotherapy for Neoadjuvant Treatment of Early Triple Negative Breast Cancer: A Single-center prospective study from Bangladesh.

Triple negative breast cancer is the kind of breast cancer that does not have any receptors which are usually found in breast cancer. It is estrogen- receptor, progesterone-receptor, and HER-2 receptor negative. About 10-15% of all breast cancers are triple negative. Its commonly seen in women aged than 40 years, and those have a BRCA-1 mutation. This is a more aggressive form of cancer, harder to treat and has chances of recurrences. The single most prognostic factor is still the pathological complete response in case of neoadjuvant (NACT)settings.